Intrinsiqq
Cadrenal Therapeutics Inc. logo

Cadrenal Therapeutics Inc. Dividend Analysis

CVKD

Compare
Dividend0
No current dividend

This company does not have a meaningful dividend profile under this framework.

Based on TTM and annual data · Not a buy/sell signal

Score Breakdown

0

Safety

40% of composite

Earnings Payout0
N/ANot reported
FCF Payout0
N/ANo data
0

Growth

35% of composite

Dividend Streak0
0YNo sustained streak
Growth Rate0
0.0%Declining
0

Income

25% of composite

Cash Yield (TTM)0
N/ANo data

Composite = Safety (0) × 0.40 + Growth (0) × 0.35 + Income (0) × 0.25 = 0

Dividend Safety

Earnings Payout

Not reported

FCF Payout

–

FCF Coverage

–

Dividend Growth

Per Share (TTM)

$16.50

Growth Streak

–

1Y CAGR

0.0%

Does Cadrenal Therapeutics (CVKD) pay a dividend?

Cadrenal Therapeutics (CVKD) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.

Frequently asked

Does Cadrenal Therapeutics (CVKD) pay a dividend?+

No. Cadrenal Therapeutics (CVKD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.

How does Cadrenal Therapeutics return cash to shareholders?+

It largely does not. Cadrenal Therapeutics pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

Could Cadrenal Therapeutics afford to pay a dividend?+

Not currently. Cadrenal Therapeutics's free cash flow is negative at -$10 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.

Which healthcare companies do pay dividends?+

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Cadrenal Therapeutics.

SourceDividend analysis computed from the 10-Q filed 16 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 17 Nov 2026. How this is calculated.

Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CVKD

CompareIntrinsic value
JUNSJupiter Neurosciences Inc.
$1.24-15.41%10
MTNBMatinas Biopharma Holdings Inc.
$0.80-1.23%40
TRAWTraws Pharma Inc.
$0.18-23.91%40
LIXTLixte Biotechnology Holdings Inc.
$2.26-20.88%0
CNTBConnect Biopharma Holdings Ltd.
$0.59-6.05%10
ATNMActinium Pharmaceuticals Inc.
$1.05-1.87%30
GNLXGenelux Corp.
$2.17-4.82%10
NRXPNRx Pharmaceuticals, Inc.
$2.15-15.69%14

Spot a number that looks wrong? Check it in CVKD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CVKD

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.